Biotest AG
XETRA:BIO
Intrinsic Value
Biotest AG is a DE-based company operating in Biotechnology industry. [ Read More ]
The intrinsic value of one BIO stock under the Base Case scenario is 36.5 EUR. Compared to the current market price of 41.6 EUR, Biotest AG is Overvalued by 12%.
Valuation Backtest
Biotest AG
Run backtest to discover the historical profit from buying and selling BIO stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Biotest AG
Current Assets | 756.5m |
Cash & Short-Term Investments | 119.4m |
Receivables | 196.8m |
Other Current Assets | 440.3m |
Non-Current Assets | 654.4m |
Long-Term Investments | 28m |
PP&E | 578.4m |
Intangibles | 15m |
Other Non-Current Assets | 33m |
Current Liabilities | 385.3m |
Accounts Payable | 78.1m |
Other Current Liabilities | 307.2m |
Non-Current Liabilities | 526.7m |
Long-Term Debt | 429.7m |
Other Non-Current Liabilities | 97m |
Earnings Waterfall
Biotest AG
Revenue
|
684.6m
EUR
|
Cost of Revenue
|
-404.3m
EUR
|
Gross Profit
|
280.3m
EUR
|
Operating Expenses
|
-160m
EUR
|
Operating Income
|
120.3m
EUR
|
Other Expenses
|
6.7m
EUR
|
Net Income
|
127m
EUR
|
Free Cash Flow Analysis
Biotest AG
What is Free Cash Flow?
BIO Profitability Score
Profitability Due Diligence
Biotest AG's profitability score is 46/100. The higher the profitability score, the more profitable the company is.
Score
Biotest AG's profitability score is 46/100. The higher the profitability score, the more profitable the company is.
BIO Solvency Score
Solvency Due Diligence
Biotest AG's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Score
Biotest AG's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BIO Price Targets Summary
Biotest AG
According to Wall Street analysts, the average 1-year price target for BIO is 33.8 EUR .
Shareholder Return
BIO Price
Biotest AG
Average Annual Return | 19.37% |
Standard Deviation of Annual Returns | 36.99% |
Max Drawdown | -30% |
Market Capitalization | 1.6B EUR |
Shares Outstanding | 38 461 500 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Biotest AG is a DE-based company operating in Biotechnology industry. The company is headquartered in Dreieich, Hessen and currently employs 1,967 full-time employees. Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology and intensive care medicine. Biotest AG develops, manufactures and markets immunoglobulin, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.
Contact
IPO
Employees
Officers
The intrinsic value of one BIO stock under the Base Case scenario is 36.5 EUR.
Compared to the current market price of 41.6 EUR, Biotest AG is Overvalued by 12%.